The story does not discuss the costs or potential savings associated with the use of this drug. On the cost side, there are the direct costs of the drug itself as well as the diagnostic testing which must be conducted prior to administering the drug. In addition, hospitals incur significant costs to become certified as a primary stroke treatment centers, which is where candidates for tPA therapy are most likely to be taken by ambulance teams. On the savings side, successful treatment with tPA would potentially prevent significant expenditures on the care of disabled stroke patients.
The story doesn’t do a good enough job explaining what they observed in the study or the benfits of tPA in general. In discussing the differences between weekday and weekend treatment, the story reports that there was a 20% difference in the likelihood of receiving tPA. In absolute terms, however, the difference between weekdays and weekends is very small (1.1% vs 0.9%). In addition, there is some discussion about why the study did not detect a reduction in deaths among patients treated on the weekend and who were more likely to receive tPA. The study could have noted that tPA has never been shown to reduce mortality in randomized clinical trials. The primary benefit of tPA—which is never explained in the story—is that it may increase the likelihood of a patient’s recovery from stroke without disability.
The story was primarily about weekday vs. weekend use of tPA. While it could have mentioned other stroke treatments with proven benefits, such as aspirin, it would probably be unfair to dock points for not including this information.
The story explains that the tPA is only used within 3 hours of the onset of stroke symptoms. It also hints at the fact that tPA is effective only for ischemic strokes, and that treatment is more likely to be available at certified stroke treatment centers. While it could have done more to make the limitations on tPA’s use explicit, the reader will probably come away with the sense that tPA is available only for certain patients where it can be used early. This is a satisfactory outcome.
Although it recites much of the same information included in an AMA press release about the study, the story includes an interview with one of the study researchers as well as with an independent expert. While this is enough for a satisfactory rating, it should be noted that the press release for this study appears to have taken a more critical view of the results than the HealthDay report. The press release stated in the first paragraph that stroke death rates were the same in this study among weekend and weekday admissions, whereas the HealthDay report took nine paragraphs to relay this information.
Systematic, Criteria-Driven
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like